SCHEMBL7928096

SCHEMBL7928096

Nc1cccc(Cl)c1OC(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
NR4A2 P43354 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GRIA1 P42261 5/20 0.36
CACNG8 Q8WXS5 5/20 0.36
BCHE P06276 6/20 0.35
ACHE P22303 6/20 0.35
CYP3A4 P08684 2/20 0.34
PIK3CA P42336 1/20 0.34
TRPV1 Q8NER1 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 2/20 0.32
CHEK1 O14757 1/20 0.32
FLT3 P36888 1/20 0.32
PLK3 Q9H4B4 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312335 0.85 CYP3A4 (0.38) TSHRALDH1A1CYP3A4PIK3CAKMT2A
SCHEMBL8978656 0.85 KMT2A (0.38) TSHRALDH1A1GRIA1CACNG8TRPV1
SCHEMBL3789699 0.80 ALDH1A1 (0.47) TSHRNR4A2ALDH1A1BCHEACHE
SCHEMBL2095845 0.76 GRIA1 (0.36) GRIA1CACNG8TRPV1CYP1A2CYP2C19
SCHEMBL10873536 0.76 GRIA1 (0.33) GRIA1CACNG8TRPV1CYP1A2CYP2C19
SCHEMBL2091796 0.76 GRIA1 (0.39) ALDH1A1GRIA1CACNG8TRPV1CYP1A2
SCHEMBL2095848 0.76 GRIA1 (0.33) ALDH1A1GRIA1CACNG8TRPV1CYP1A2
SCHEMBL2091798 0.76 TSHR (0.45) TSHRALDH1A1GRIA1CACNG8TRPV1
SCHEMBL29937335 0.76 GRIA1 (0.33) GRIA1CACNG8TRPV1CYP1A2CYP2C19
SCHEMBL16957701 0.76 GRIA1 (0.33) GRIA1CACNG8TRPV1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6235939-B1 TRIFLUOROALKOXY-5-CHLOROANILINE BAYER AKTIENGESELLSCHAFT (DE) 2001-05-22 US claimed
EP-0546391-A2 Process for the preparation of fluorine containing anilines. BAYER AG (DE) 1993-06-16 EP claimed
US-20240101576-A1 HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2024-03-28 US disclosed
CN-116981667-A Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment 蝎子疗法股份有限公司 2023-10-31 CN disclosed
US-6235939-B1 TRIFLUOROALKOXY-5-CHLOROANILINE BAYER AKTIENGESELLSCHAFT (DE) 2001-05-22 US disclosed
US-6077973-A Process for the preparation of anilines which contain fluorine and new anilines which contain fluorine BAYER AKTIENGESELLSCHAFT (DE) 2000-06-20 US disclosed
EP-0546391-B1 Process for the preparation of fluorine containing anilines. BAYER AG (DE) 1996-05-08 EP disclosed
EP-0546391-A2 Process for the preparation of fluorine containing anilines. BAYER AG (DE) 1993-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101576-A1 HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER ERBB2, EGFR, ERBB3 TSHR 625/4885NR4A2 919/4885ALDH1A1 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.